VXRT250117C1000
- 0.10
- +0.05+100.00%
Vaxart Newsroom
Vaxart Gets Increased Funding for COVID-19 Pill Vaccine Study
Vaxart Project Agreement Change Ups Funding for Oral COVID Vaccine Candidate
Express News | Vaxart - Funding Ceiling Increased to About $460.7 Million; Funding for Trial Increased to About $134.2 Million
Express News | Vaxart Inc - Enters Into Modification No. 4 to Project Agreement With Advanced Technology International
Vaxart Completes Enrollment Of The Sentinel Cohort In Its Phase 2b Study Of Its COVID-19 Oral Pill Vaccine Candidate
Express News | Vaxart Completes Enrollment of Sentinel Cohort in Phase 2B Study Evaluating Its Covid-19 Oral Pill Vaccine Candidate
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Express News | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
B.Riley Financial Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $2.5
Vaxart's Promising Advancements in Oral Vaccine Development and Norovirus Program Drive Buy Rating
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
Oppenheimer Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $4
Vaxart (VXRT) Receives a Buy From Oppenheimer
Vaxart's Q3 2024: Progress in Oral Vaccine Development
Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript Summary
Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates
Vaxart | 8-K: Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results